Evotec Launches Biomanufacturing Facility in France
The new facility, which will be Evotec’s first in Europe, will aim to offer capacity, flexibility, and quality for biotherapeutic development and manufacturing while utilizing technology that employs small, automated, highly intensified, and continuous bioprocessing operations inside autonomous cleanrooms.
Evotec announced on April 20, 2021 that it has started the construction of its new J.POD 2 EU cGMP biomanufacturing facility in France.
The new facility, which will be Evotec’s first in Europe, will aim to offer capacity, flexibility, and quality for biotherapeutic development and manufacturing while utilizing its subsidiary Just – Evotec Biologics’ technology that employs small, automated, highly intensified, and continuous bioprocessing operations inside autonomous cleanrooms, Evotec said in a company press release.
“The global availability and accessibility of highly effective biotherapeutics has been Just – Evotec Biologics’ mission right from the start,” said Werner Lanthaler, CEO of Evotec, in the press release. “The ongoing coronavirus pandemic has underlined the need for flexible and nearshore biomanufacturing capacities. We are very grateful that through the support of the French government as well as all local institutions, we can now continue to deliver on this mission with the construction of Europe’s first J.POD facility, this is critical for society.”
Source: Evotec
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Digital Transformation in the Biopharma Industry
October 19th 2023In this episode of the Drug Solutions Podcast, industry experts discuss the challenges and advantages of the digitalization trend in the biopharma industry, with particular emphasis on the impacts to biomanufacturing.
